{"id":"NCT03142451","sponsor":"Vyne Therapeutics Inc.","briefTitle":"A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea","officialTitle":"A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea (FX2016-11)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-02","primaryCompletion":"2018-08-31","completion":"2018-09-28","firstPosted":"2017-05-05","resultsPosted":"2020-12-17","lastUpdate":"2021-01-29"},"enrollment":751,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Facial Papulopustular Rosacea"],"interventions":[{"type":"DRUG","name":"FMX103 minocycline foam 1.5%","otherNames":[]},{"type":"DRUG","name":"Vehicle foam","otherNames":[]}],"arms":[{"label":"FMX103 1.5%","type":"EXPERIMENTAL"},{"label":"Vehicle foam","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.","primaryOutcome":{"measure":"The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"FMX103 1.5%","deltaMin":17.56,"sd":0.442},{"arm":"Vehicle Foam","deltaMin":15.34,"sd":0.604}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0031"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":54,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":494},"commonTop":["Upper respiratory tract infection"]}}